Form 4: Scilex Director Jay Chun Receives Stock Options

Scilex Holding Co. Director Jay Chun was granted 20,000 nonstatutory stock options with an exercise price of $17.58, vesting monthly over four years.

Summary

• Director Jay Chun of Scilex Holding Co. (SCLX) was granted 20,000 nonstatutory stock options.
• The options have an exercise price of $17.58 per share.
• The grant date for these options was October 8, 2025.
• The options will vest monthly at a rate of 1/48th of the total shares, commencing from the grant date.
• Full vesting is contingent upon Mr. Chun's continued service to the Issuer.
• The options have an expiration date of October 8, 2035.
• Following this transaction, Mr. Chun beneficially owns 20,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, as it aligns the director's interests with shareholders and incentivizes long-term performance. It's a standard compensation practice, indicating stability and a focus on future growth, without immediate negative implications.

Positives

• Aligns the director's financial interests with those of shareholders, incentivizing long-term company performance.
• Provides a retention mechanism for key management personnel through the vesting schedule.
• Standard practice for compensating directors, reflecting confidence in future growth.

Negatives

• Potential for future share dilution if options are exercised, though this is a common aspect of equity compensation.
• The value of the options is dependent on the future stock price exceeding the exercise price, introducing market risk.

Risks

• Market volatility could impact the value of the stock options, potentially rendering them out-of-the-money.
• Risk of non-vesting if the reporting person's service to the issuer ceases.
• Future dilution from option exercise could slightly reduce earnings per share for existing shareholders.

Future Outlook

The grant of stock options to a director suggests an incentive for long-term commitment and performance, aligning management's future financial success with the company's stock price appreciation over the next decade.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and motivate key personnel by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The use of nonstatutory stock options as a component of director compensation is a standard practice observed across various industries, including biotechnology, aligning with compensation structures at companies like Amgen Inc. or Gilead Sciences, Inc.
• A 4-year monthly vesting schedule (1/48th per month) is a typical duration for equity grants designed to ensure long-term retention and incentivize sustained performance, comparable to vesting schedules seen at peer companies.
• The exercise price being set at the market price on the grant date is standard for at-the-money options, a common approach to ensure the options gain value only if the company's stock price appreciates.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value creation, but also potential for future dilution upon exercise.
• Employees: No direct impact mentioned, but general positive sentiment from stable governance.
• Management: Director's compensation structure is enhanced, providing long-term incentives.

Next Steps

• Jay Chun's continued service to Scilex Holding Co. is required for the monthly vesting of the granted stock options.

Key Dates

Keywords

Scilex Holding Co, SCLX, Jay Chun, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule